Nasal high flow reduces hypercapnia by clearance of anatomical dead space in a COPD patient

Kathrin Fricke, Stanislav Tatkov, Ulrike Domanski, Karl Josef Franke, Georg Nilius, Hartmut Schneider

Research output: Contribution to journalArticle

Abstract

Chronic obstructive pulmonary disease (COPD) with hypercapnia is associated with increased mortality. Non-invasive ventilation (NIV) can lower hypercapnia and ventilator loads but is hampered by a low adherence rate leaving a majority of patients insufficiently treated. Recently, nasal high flow (NHF) has been introduced in the acute setting in adults, too. It is an open nasal cannula system for delivering warm and humidified air or oxygen at high flow rates (2–50 L/min) assisting ventilation. It was shown that this treatment can improve hypercapnia. The mechanism of reducing arterial carbon dioxide (CO2) is proposed through a reduction in nasal dead space ventilation, but there are no studies in which dead space volume was measured in spontaneously breathing subjects. In our case report we measured in a tracheostomized COPD patient CO2 and pressure via sealed ports in the tracheostomy cap and monitored transcutaneous CO2 and tidal volumes. NHF (30 L/min mixed with 3 L/min oxygen) was administered repeatedly at 15-minutes intervals. Inspired CO2 decreased instantly with onset of NHF, followed by a reduction in transcutaneous/arterial CO2. Minute ventilation on nasal high flow was also reduced by 700 ml, indicating that nasal high flow led to a reduction of dead space ventilation thereby improving alveolar ventilation. In conclusion, NHF assist ventilation through clearance of anatomical dead space, which improves alveolar ventilation. Since the reduction in hypercapnia was similar to that reported with effective NIV treatment NHF may become an alternative to NIV in hypercapnic respiratory failure.

Original languageEnglish (US)
Pages (from-to)115-117
Number of pages3
JournalRespiratory Medicine Case Reports
Volume19
DOIs
StatePublished - 2016

Fingerprint

Hypercapnia
Nose
Chronic Obstructive Pulmonary Disease
Ventilation
Noninvasive Ventilation
Oxygen
Tracheostomy
Tidal Volume
Mechanical Ventilators
Carbon Dioxide
Respiratory Insufficiency
Respiration
Air
Pressure
Mortality
Therapeutics

Keywords

  • Chronic obstructive pulmonary disease
  • Dead space ventilation
  • Hypercapnic respiratory failure
  • Nasal high flow

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Nasal high flow reduces hypercapnia by clearance of anatomical dead space in a COPD patient. / Fricke, Kathrin; Tatkov, Stanislav; Domanski, Ulrike; Franke, Karl Josef; Nilius, Georg; Schneider, Hartmut.

In: Respiratory Medicine Case Reports, Vol. 19, 2016, p. 115-117.

Research output: Contribution to journalArticle

Fricke, Kathrin ; Tatkov, Stanislav ; Domanski, Ulrike ; Franke, Karl Josef ; Nilius, Georg ; Schneider, Hartmut. / Nasal high flow reduces hypercapnia by clearance of anatomical dead space in a COPD patient. In: Respiratory Medicine Case Reports. 2016 ; Vol. 19. pp. 115-117.
@article{29d14efc04004ed9aac5804d15b75491,
title = "Nasal high flow reduces hypercapnia by clearance of anatomical dead space in a COPD patient",
abstract = "Chronic obstructive pulmonary disease (COPD) with hypercapnia is associated with increased mortality. Non-invasive ventilation (NIV) can lower hypercapnia and ventilator loads but is hampered by a low adherence rate leaving a majority of patients insufficiently treated. Recently, nasal high flow (NHF) has been introduced in the acute setting in adults, too. It is an open nasal cannula system for delivering warm and humidified air or oxygen at high flow rates (2–50 L/min) assisting ventilation. It was shown that this treatment can improve hypercapnia. The mechanism of reducing arterial carbon dioxide (CO2) is proposed through a reduction in nasal dead space ventilation, but there are no studies in which dead space volume was measured in spontaneously breathing subjects. In our case report we measured in a tracheostomized COPD patient CO2 and pressure via sealed ports in the tracheostomy cap and monitored transcutaneous CO2 and tidal volumes. NHF (30 L/min mixed with 3 L/min oxygen) was administered repeatedly at 15-minutes intervals. Inspired CO2 decreased instantly with onset of NHF, followed by a reduction in transcutaneous/arterial CO2. Minute ventilation on nasal high flow was also reduced by 700 ml, indicating that nasal high flow led to a reduction of dead space ventilation thereby improving alveolar ventilation. In conclusion, NHF assist ventilation through clearance of anatomical dead space, which improves alveolar ventilation. Since the reduction in hypercapnia was similar to that reported with effective NIV treatment NHF may become an alternative to NIV in hypercapnic respiratory failure.",
keywords = "Chronic obstructive pulmonary disease, Dead space ventilation, Hypercapnic respiratory failure, Nasal high flow",
author = "Kathrin Fricke and Stanislav Tatkov and Ulrike Domanski and Franke, {Karl Josef} and Georg Nilius and Hartmut Schneider",
year = "2016",
doi = "10.1016/j.rmcr.2016.08.010",
language = "English (US)",
volume = "19",
pages = "115--117",
journal = "Respiratory Medicine Case Reports",
issn = "2213-0071",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Nasal high flow reduces hypercapnia by clearance of anatomical dead space in a COPD patient

AU - Fricke, Kathrin

AU - Tatkov, Stanislav

AU - Domanski, Ulrike

AU - Franke, Karl Josef

AU - Nilius, Georg

AU - Schneider, Hartmut

PY - 2016

Y1 - 2016

N2 - Chronic obstructive pulmonary disease (COPD) with hypercapnia is associated with increased mortality. Non-invasive ventilation (NIV) can lower hypercapnia and ventilator loads but is hampered by a low adherence rate leaving a majority of patients insufficiently treated. Recently, nasal high flow (NHF) has been introduced in the acute setting in adults, too. It is an open nasal cannula system for delivering warm and humidified air or oxygen at high flow rates (2–50 L/min) assisting ventilation. It was shown that this treatment can improve hypercapnia. The mechanism of reducing arterial carbon dioxide (CO2) is proposed through a reduction in nasal dead space ventilation, but there are no studies in which dead space volume was measured in spontaneously breathing subjects. In our case report we measured in a tracheostomized COPD patient CO2 and pressure via sealed ports in the tracheostomy cap and monitored transcutaneous CO2 and tidal volumes. NHF (30 L/min mixed with 3 L/min oxygen) was administered repeatedly at 15-minutes intervals. Inspired CO2 decreased instantly with onset of NHF, followed by a reduction in transcutaneous/arterial CO2. Minute ventilation on nasal high flow was also reduced by 700 ml, indicating that nasal high flow led to a reduction of dead space ventilation thereby improving alveolar ventilation. In conclusion, NHF assist ventilation through clearance of anatomical dead space, which improves alveolar ventilation. Since the reduction in hypercapnia was similar to that reported with effective NIV treatment NHF may become an alternative to NIV in hypercapnic respiratory failure.

AB - Chronic obstructive pulmonary disease (COPD) with hypercapnia is associated with increased mortality. Non-invasive ventilation (NIV) can lower hypercapnia and ventilator loads but is hampered by a low adherence rate leaving a majority of patients insufficiently treated. Recently, nasal high flow (NHF) has been introduced in the acute setting in adults, too. It is an open nasal cannula system for delivering warm and humidified air or oxygen at high flow rates (2–50 L/min) assisting ventilation. It was shown that this treatment can improve hypercapnia. The mechanism of reducing arterial carbon dioxide (CO2) is proposed through a reduction in nasal dead space ventilation, but there are no studies in which dead space volume was measured in spontaneously breathing subjects. In our case report we measured in a tracheostomized COPD patient CO2 and pressure via sealed ports in the tracheostomy cap and monitored transcutaneous CO2 and tidal volumes. NHF (30 L/min mixed with 3 L/min oxygen) was administered repeatedly at 15-minutes intervals. Inspired CO2 decreased instantly with onset of NHF, followed by a reduction in transcutaneous/arterial CO2. Minute ventilation on nasal high flow was also reduced by 700 ml, indicating that nasal high flow led to a reduction of dead space ventilation thereby improving alveolar ventilation. In conclusion, NHF assist ventilation through clearance of anatomical dead space, which improves alveolar ventilation. Since the reduction in hypercapnia was similar to that reported with effective NIV treatment NHF may become an alternative to NIV in hypercapnic respiratory failure.

KW - Chronic obstructive pulmonary disease

KW - Dead space ventilation

KW - Hypercapnic respiratory failure

KW - Nasal high flow

UR - http://www.scopus.com/inward/record.url?scp=84986557900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986557900&partnerID=8YFLogxK

U2 - 10.1016/j.rmcr.2016.08.010

DO - 10.1016/j.rmcr.2016.08.010

M3 - Article

VL - 19

SP - 115

EP - 117

JO - Respiratory Medicine Case Reports

JF - Respiratory Medicine Case Reports

SN - 2213-0071

ER -